Literature DB >> 3553496

Work performance, absenteeism and antihypertensive medications.

S H Croog, A Sudilovsky, S Levine, M A Testa.   

Abstract

Relationships between antihypertensive medications and selected aspects of work performance and absenteeism were explored in a multicentre, randomized, double-blind, clinical trial with 626 male hypertensive patients assigned to regimens of captopril, methyldopa or propranolol, either alone or supplemented as needed by a diuretic for blood pressure control. Patients previously on antihypertensive therapy did not differ from new patients in work absenteeism, both before and throughout the clinical trial. After a 24-week treatment period patients on captopril alone improved significantly over baseline in work-performance measures of mental acuity and job satisfaction-morale, while significant worsening in the methyldopa group and no change in the propranolol group occurred among patients given these drugs alone. When 24-week changes between groups not on diuretic were compared, significant differences in the measures appeared in favour of captopril. However, patients also taking a diuretic did not differ from baseline either within or between the three groups. Withdrawal from the trial because of lethargy and fatigue was significantly greater among patients on methyldopa and propranolol than among those receiving captopril. Absenteeism did not differ between the drug groups. The study shows that there are measurable differences in the impact of the antihypertensive drugs on aspects of work performance, and it underlines the importance of considering this factor in assigning patients to therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3553496

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  9 in total

1.  Interaction of occupational and personal risk factors in workforce health and safety.

Authors:  Paul A Schulte; Sudha Pandalai; Victoria Wulsin; HeeKyoung Chun
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

Review 2.  Employee health and presenteeism: a systematic review.

Authors:  Alyssa B Schultz; Dee W Edington
Journal:  J Occup Rehabil       Date:  2007-07-25

3.  Health-related quality of life assessment and the pharmaceutical industry.

Authors:  D A Revicki; M Rothman; B Luce
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 4.  Drug treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Hypertension and sickness absence: the role of perceived symptoms.

Authors:  S Melamed; P Froom; M S Green
Journal:  J Behav Med       Date:  1997-10

Review 6.  Quality of life as a therapeutic end-point. An analysis of therapeutic trials in hypertension.

Authors:  N K Hollenberg; M Testa; G H Williams
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

7.  Nootropic effects of ACE inhibitors in mice.

Authors:  C Mondadori; P Etienne
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood.

Authors:  D Currie; R V Lewis; D G McDevitt; A N Nicholson; N A Wright
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

Review 9.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  J C Soares; S Gershon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.